AOD-9604 History and Development: From HGH Fragment to Investigational Fat-Loss Peptide

Discovery at Monash University: Isolating the Fat-Loss Fragment

AOD-9604 was born from a straightforward question: could researchers isolate the fat-burning properties of human growth hormone while discarding its unwanted metabolic effects? In the early 1990s, a team led by Professor Frank Ng at Monash University in Melbourne, Australia, set out to answer that question by systematically fragmenting the HGH molecule.

Growth hormone is a 191-amino-acid protein secreted by the anterior pituitary gland. Its full-length form activates the GH receptor (GHR), producing a wide array of downstream effects: increased lean mass, enhanced lipolysis, but also insulin resistance, fluid retention, and acromegalic changes when administered exogenously at supraphysiologic doses 1. The clinical problem was clear. Patients receiving recombinant HGH (somatropin) for fat reduction experienced glycemic deterioration and other dose-limiting toxicities.

Ng's laboratory identified a small C-terminal region of HGH, spanning residues 176 through 191, that retained lipolytic activity in adipocyte bioassays. This 16-amino-acid fragment did not bind the classical GH receptor and did not stimulate IGF-1 production. The fragment was then stabilized through a single modification: cyclization of the C-terminal cysteine residue (Cys-182 to Cys-189 disulfide bond), yielding the compound designated AOD-9604 2. Metabolic Pharmaceuticals Ltd, an Australian biopharmaceutical company listed on the ASX under the ticker MBP, acquired the licensing rights from Monash University and funded the translational program.

The Heffernan Study (2001): Proof of Concept in Animal Models

The 2001 publication by Heffernan and colleagues in Endocrinology remains the foundational preclinical paper for AOD-9604. The study tested the peptide in obese (ob/ob) mice and demonstrated statistically significant reductions in body fat over a 19-day chronic dosing period, with no detectable changes in IGF-1 levels, blood glucose, or insulin sensitivity 2.

Three findings from this study shaped the entire development program. First, AOD-9604 reduced fat mass by approximately 50% relative to saline controls in the ob/ob mouse model. Second, the peptide did not produce the anti-insulin effects associated with full-length HGH administration. Third, the compound did not stimulate longitudinal bone growth or organ hypertrophy, confirming that its activity was mechanistically distinct from GH receptor activation.

The Heffernan data gave Metabolic Pharmaceuticals the preclinical package needed to file an Investigational New Drug (IND) application and move into human trials. No other research group had successfully demonstrated a fat-selective GH fragment with such a clean separation from GHR-mediated side effects 2. The paper has been cited over 100 times and remains the most referenced primary source in the AOD-9604 literature.

Proposed Mechanism: How AOD-9604 Stimulates Fat Breakdown

AOD-9604 does not work through the growth hormone receptor. This point is critical because it explains both the peptide's safety profile in early studies and its limited anabolic activity.

The proposed mechanism involves stimulation of lipolysis (fat breakdown) and simultaneous inhibition of lipogenesis (new fat synthesis) through a pathway that appears to involve beta-3 adrenergic receptor signaling in white adipose tissue 2. In vitro studies using murine 3T3-L1 adipocytes showed that AOD-9604 increased the release of glycerol (a marker of triglyceride hydrolysis) in a dose-dependent manner. When researchers co-administered beta-3 adrenergic receptor antagonists, the lipolytic effect was attenuated, implicating this receptor subtype in the signaling cascade 3.

Unlike recombinant HGH, AOD-9604 does not raise serum IGF-1 concentrations. This is a direct consequence of its inability to activate the JAK2-STAT5 signaling pathway downstream of GHR. The clinical implication: AOD-9604 should not carry the proliferative risks (theoretical cancer promotion, acromegaly) associated with sustained IGF-1 elevation 1.

One open question that remains unresolved: the exact binding target of AOD-9604 has not been definitively identified. The peptide does not fit into the classical GH receptor binding pocket, and the beta-3 receptor interaction may be indirect. Some researchers have proposed that the fragment interacts with a distinct adipocyte surface protein that has not yet been cloned or characterized, though this hypothesis lacks published confirmation.

Human Clinical Trials: Phase I Through Phase IIb

Metabolic Pharmaceuticals conducted a series of human studies between 2001 and 2007. The clinical program moved rapidly by contemporary standards, with Phase I safety data in hand by 2002.

Phase I (2001-2002). An initial safety and pharmacokinetic study enrolled healthy volunteers who received subcutaneous injections of AOD-9604 at escalating doses. The peptide was well tolerated, with injection site reactions as the most common adverse event. No changes in fasting glucose, insulin, or IGF-1 were observed, confirming the preclinical finding that the fragment does not activate classical GH signaling 4.

Phase IIa (2003-2004). A small proof-of-concept trial in obese subjects (BMI 30-40 kg/m²) tested subcutaneous AOD-9604 at 1 mg daily for 12 weeks. The study met its primary safety endpoints and reported trends toward fat mass reduction versus placebo, though the sample size was too small for statistical significance on efficacy endpoints.

Phase IIb (2004-2007). Metabolic Pharmaceuticals pivoted to an oral formulation for the larger Phase IIb trial, enrolling approximately 300 obese adults across multiple Australian sites. This decision proved consequential. The oral bioavailability of a 16-amino-acid peptide is inherently low due to gastric proteolysis, and the trial ultimately failed to demonstrate statistically significant weight loss versus placebo at the primary 24-week endpoint 5.

The Phase IIb failure in 2007 effectively ended Metabolic Pharmaceuticals' AOD-9604 obesity program. The company's stock declined sharply, and the weight-loss indication was shelved. Whether the failure reflected true lack of efficacy or simply inadequate oral delivery remains debated. No injectable Phase IIb trial in humans was ever completed.

Post-Trial Developments: GRAS Status and Compounding

After the clinical program stalled, AOD-9604 took an unusual regulatory path. In 2014, the compound received a "Generally Recognized as Safe" (GRAS) designation from the FDA under GRAS Notice No. GRN 000620 for use as an ingredient in food products at low oral doses 6. This filing was submitted by a successor entity to Metabolic Pharmaceuticals.

The GRAS designation is often misunderstood. It applies exclusively to oral AOD-9604 as a food additive at specified concentrations. It does not constitute FDA approval for AOD-9604 as a drug product, and it does not authorize injectable formulations. The distinction matters because the majority of current clinical use involves subcutaneous injection, a route that falls outside the GRAS determination entirely.

Around the same time, the Australian company CalzBone Pty Ltd acquired certain AOD-9604 intellectual property and explored applications in cartilage repair (osteoarthritis). A small Australian trial investigated intra-articular injection of AOD-9604 for knee osteoarthritis, though results have not been published in peer-reviewed journals as of 2026 7.

FDA Regulatory Status: Not an Approved Drug

AOD-9604 is not FDA-approved for any therapeutic indication. It is not listed in the FDA's Orange Book, and it does not have a valid New Drug Application (NDA) or Biologics License Application (BLA) on file.

The peptide is currently available in the United States through 503A compounding pharmacies, which prepare patient-specific prescriptions under the Federal Food, Drug, and Cosmetic Act Section 503A. This pathway requires a valid prescription from a licensed provider, and the compounding pharmacy must meet state board of pharmacy requirements 8.

In June 2023, the FDA added certain peptides to its list of bulk drug substances under evaluation for inclusion on the 503B outsourcing facility bulks list. AOD-9604's long-term availability through compounding pharmacies depends on ongoing FDA review processes. Providers prescribing AOD-9604 should monitor FDA enforcement actions and category nominations that could affect compounding eligibility.

The World Anti-Doping Agency (WADA) prohibited AOD-9604 under section S0 (non-approved substances) of its Prohibited List. Several high-profile doping cases in professional sports have involved AOD-9604, including investigations in Australian Rules Football (AFL) in 2013 9.

The Oral vs. Injectable Question: Why the Route Matters

A recurrent theme in AOD-9604's development history is the tension between oral and injectable delivery. The Phase IIb failure used an oral formulation, and some clinicians argue this confounded the efficacy signal.

Peptides consisting of 16 amino acids face extensive first-pass metabolism. Gastric acid and pepsin cleave peptide bonds within minutes, and hepatic enzymes further degrade any fraction that reaches the portal circulation. Oral bioavailability for unprotected peptides of this size is typically <2% 10. By contrast, subcutaneous injection bypasses the GI tract entirely, delivering the intact peptide directly into the systemic circulation with bioavailability estimates exceeding 90%.

The current clinical convention for AOD-9604, a subcutaneous injection of 250-300 mcg once daily, reflects the injectable route's pharmacokinetic advantage. No head-to-head trial has compared oral versus subcutaneous AOD-9604 at bioequivalent exposures. This gap in the evidence base is significant: the compound's "failure" in the Phase IIb trial may have been a failure of the delivery method rather than the molecule itself.

Current Research Directions and Open Questions

Several lines of investigation remain active as of 2026, though none have reached late-stage clinical development.

Osteoarthritis. CalzBone's intra-articular program explored whether AOD-9604 could stimulate proteoglycan synthesis in cartilage. Early in vitro data suggested chondroprotective activity, but no Phase II trial results have been published in indexed journals 7.

Combination peptide therapy. Some compounding providers offer AOD-9604 in combination with CJC-1295 (a growth hormone-releasing hormone analog) or ipamorelin (a ghrelin mimetic). The rationale is additive or synergistic fat-loss effects. No randomized controlled trial has tested these combinations, and the safety profile of multi-peptide stacking is unknown.

Metabolic syndrome endpoints. Given AOD-9604's apparent lack of glucotoxicity, researchers have proposed studying it in patients with metabolic syndrome where GH-based therapies are contraindicated due to insulin resistance. This population could theoretically benefit from lipolysis enhancement without glycemic deterioration, but the hypothesis remains untested in controlled human studies.

The absence of Phase III data is the single largest limitation in AOD-9604's evidence base. Without a completed registrational trial, the compound cannot be evaluated by standard evidence-based medicine criteria (Oxford Level 1 or GRADE high-certainty). Clinicians prescribing AOD-9604 through compounding pharmacies should disclose this evidence gap to patients as part of informed consent.

As of 2026, the Endocrine Society and the American Association of Clinical Endocrinology (AACE) have not issued guideline recommendations for or against AOD-9604 in any clinical context.

Timeline of Key Milestones

The development arc of AOD-9604 spans more than three decades. Here are the major events in chronological order.

1. Early 1990s. Frank Ng's laboratory at Monash University identifies the C-terminal fragment of HGH with lipolytic properties.
2. 1997-1999. Metabolic Pharmaceuticals Ltd acquires commercial rights from Monash University.
3. 2001. Heffernan et al. publish the foundational preclinical study in Endocrinology, showing fat reduction in ob/ob mice without GHR activation 2.
4. 2002. Phase I safety trial in healthy volunteers demonstrates tolerability and no IGF-1 elevation.
5. 2003-2004. Phase IIa proof-of-concept trial in obese adults.
6. 2004-2007. Phase IIb oral formulation trial enrolls approximately 300 subjects. Fails to meet primary weight-loss endpoint.
7. 2007. Metabolic Pharmaceuticals shelves the obesity indication.
8. 2013. WADA bans AOD-9604; the Essendon AFL doping investigation brings the peptide into public awareness 9.
9. 2014. FDA issues GRAS Notice No. GRN 000620 for oral AOD-9604 as a food ingredient 6.
10. 2015-present. CalzBone explores osteoarthritis indication; 503A compounding pharmacies begin supplying injectable AOD-9604 under physician prescription.